Patents by Inventor Eric Ostertag

Eric Ostertag has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human monoclonal autoantibodies to ADAMTS13 and uses thereof
    Patent number: 11597778
    Abstract: The present invention relates to compositions and methods of use of anti-ADAMTS13 autoantibodies and fragments thereof. In one aspect, the invention includes a composition comprising an isolated anti-ADAMTS13 autoantibody or fragment thereof. In other aspects, methods are described for generating an in vivo model of thrombotic thrombocytopenic purpura (TTP) comprising introducing at least one anti-ADAMTS13 autoantibody or fragment thereof into a model organism and identifying an anti-autoimmune reagent for treating TTP.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 7, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Donald L. Siegel, Stephen Kacir, Eric Ostertag, X. Long Zheng
  • Compositions and methods for directing proteins to specific loci in the genome
    Patent number: 11473082
    Abstract: Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a fusion protein comprising a DNA localization component and an effector molecule. Preferred embodiments of the disclosure include, but are not limited to, the following fusion proteins: dSaCas9-Clo051, dCas9-Clo051, Xanthomonas-TALE-Clo051, and Ralstonia-TALE-Clo051.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: October 18, 2022
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric Ostertag, Tseten Yeshi, Xianghong Li
  • Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
    Patent number: 11213594
    Abstract: Disclosed are compositions for delivering gene editing molecules to a cell. Exemplary compositions comprise a micelle assembled from a plurality of triblock copolymers, wherein each triblock copolymer having at least one hydrophobic block, at least one hydrophilic block, and at least one poly(L-histidine) block, wherein: the at least one poly(L-histidine) block complexes with the at least one gene editing molecule; and the at least one poly(L-histidine) block is capable of a pH dependent release of the at least one gene editing molecule.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: January 4, 2022
    Assignee: POSEIDA THERAPEUTICS, INC.
    Inventors: Paiman Peter Ghoroghchian, Gabriela Romero Uribe, Eric Ostertag
  • TRANSPOSON SYSTEM AND METHODS OF USE
    Publication number: 20210115453
    Abstract: Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
    Type: Application
    Filed: August 31, 2018
    Publication date: April 22, 2021
    Inventors: Devon SHEDLOCK, David HERMANSON, Eric OSTERTAG, Maximilian RICHTER, Stacey Ann CRANERT
  • TRANSPOSON SYSTEM AND METHODS OF USE
    Publication number: 20200063157
    Abstract: Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
    Type: Application
    Filed: December 20, 2017
    Publication date: February 27, 2020
    Inventors: Devon SHEDLOCK, David HERMANSON, Eric OSTERTAG
  • Modified stem cell memory T cells, methods of making and methods of using same
    Patent number: 10513686
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: December 24, 2019
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric Ostertag, Devon Shedlock
  • CHIMERIC ANTIGEN RECEPTORS (CARS) SPECIFIC FOR MUC1 AND METHODS FOR THEIR USE
    Publication number: 20190328784
    Abstract: Disclosed are MUC1-CAR compositions and methods for use of these compositions to target a MUC1 protein, including CARTyrin compositions, wherein the cell expressing the targeted MUC1 protein may be targeted and killed by, for instance, a cytotoxic T cell.
    Type: Application
    Filed: July 17, 2017
    Publication date: October 31, 2019
    Inventors: Eric Ostertag, Devon Shedlock
  • Modified stem cell memory T cells, methods of making and methods of using same
    Patent number: 10415016
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 17, 2019
    Assignee: POSEIDA THERAPEUTICS, INC.
    Inventors: Eric Ostertag, Devon Shedlock
  • POLY(HISTIDINE)-BASED MICELLES FOR COMPLEXATION AND DELIVERY OF PROTEINS AND NUCLEIC ACIDS
    Publication number: 20190255191
    Abstract: Disclosed are compositions for delivering gene editing molecules to a cell. Exemplary compositions comprise a micelle assembled from a plurality of triblock copolymers, wherein each triblock copolymer having at least one hydrophobic block, at least one hydrophilic block, and at least one poly(L-histidine) block, wherein: the at least one poly(L-histidine) block complexes with the at least one gene editing molecule; and the at least one poly(L-histidine) block is capable of a pH dependent release of the at least one gene editing molecule.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 22, 2019
    Inventors: Paiman Peter GHOROGHCHIAN, Gabriela ROMERO URIBE, Eric OSTERTAG
  • Modified stem cell memory T cells, methods of making and methods of using same
    Patent number: 10329543
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 25, 2019
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric Ostertag, Devon Shedlock
  • TRANSPOSON SYSTEM AND METHODS OF USE
    Publication number: 20190185880
    Abstract: Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 20, 2019
    Inventors: Devon SHEDLOCK, David HERMANSON, Eric OSTERTAG
  • CHIMERIC ANTIGEN RECEPTORS AND METHODS FOR USE
    Publication number: 20190177421
    Abstract: Disclosed are chimeric antigen receptors (CARs) comprising Centyrins (i.e. CARTyrins), transposons encoding CARs and CARTyrins of the disclosure, cells modified to express CARs and CARTyrins of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.
    Type: Application
    Filed: July 17, 2017
    Publication date: June 13, 2019
    Inventors: Eric Ostertag, Devon Shedlock
  • Hyperactive PiggyBac transposases
    Patent number: 10287559
    Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 14, 2019
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric Ostertag, Blair Madison
  • MODIFIED STEM CELL MEMORY T CELLS, METHODS OF MAKING AND METHODS OF USING SAME
    Publication number: 20190119658
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Application
    Filed: October 23, 2017
    Publication date: April 25, 2019
    Inventors: Eric OSTERTAG, Devon SHEDLOCK
  • MODIFIED STEM CELL MEMORY T CELLS, METHODS OF MAKING AND METHODS OF USING SAME
    Publication number: 20190119636
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Application
    Filed: October 23, 2017
    Publication date: April 25, 2019
    Inventors: Eric OSTERTAG, Devon SHEDLOCK
  • MODIFIED STEM CELL MEMORY T CELLS, METHODS OF MAKING AND METHODS OF USING SAME
    Publication number: 20190119637
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Application
    Filed: January 31, 2018
    Publication date: April 25, 2019
    Inventors: Eric OSTERTAG, Devon SHEDLOCK
  • MODIFIED STEM CELL MEMORY T CELLS, METHODS OF MAKING AND METHODS OF USING SAME
    Publication number: 20190119640
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Application
    Filed: October 10, 2018
    Publication date: April 25, 2019
    Inventors: Eric OSTERTAG, Devon SHEDLOCK
  • HUMAN MONOCLONAL AUTOANTIBODIES TO ADAMTS13 AND USES THEREOF
    Publication number: 20190031771
    Abstract: The present invention relates to compositions and methods of use of anti-ADAMTS13 autoantibodies and fragments thereof. In one aspect, the invention includes a composition comprising an isolated anti-ADAMTS13 autoantibody or fragment thereof. In other aspects, methods are described for generating an in vivo model of thrombotic thrombocytopenic purpura (TTP) comprising introducing at least one anti-ADAMTS13 autoantibody or fragment thereof into a model organism and identifying an anti-autoimmune reagent for treating TTP.
    Type: Application
    Filed: April 6, 2016
    Publication date: January 31, 2019
    Inventors: Donald L. SIEGEL, Stephen KACIR, Eric OSTERTAG, X. Long ZHENG
  • Hyperactive piggybac transposases
    Patent number: 10131885
    Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 20, 2018
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric Ostertag, Blair Madison
  • COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME
    Publication number: 20180187185
    Abstract: Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a fusion protein comprising a DNA localization component and an effector molecule. Preferred embodiments of the disclosure include, but are not limited to, the following fusion proteins: dSaCas9-Clo051, dCas9-Clo051, Xanthomonas-TALE-Clo051, and Ralstonia-TALE-Clo051.
    Type: Application
    Filed: June 16, 2016
    Publication date: July 5, 2018
    Inventors: Eric OSTERTAG, Tseten YESHI, Xianghong LI